BRIEF—Rubraca now reimbursed and available in France

US drugmaker Clovis Oncology today announced that Rubraca (rucaparib) is now available and reimbursed in France.

Rubraca is an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.

Rucaparib is indicated for eligible patients regardless of BRCA status, which means it can be prescribed for women who harbor a BRCA mutation or who are BRCA wild-type.

Around 5,000 women are diagnosed with ovarian cancer in France every year, which equates to roughly 14 every day.

Ovarian cancer is the eighth most common cancer in women and the fourth most fatal cancer in France.